智飞生物涨2.02%，成交额2.89亿元，主力资金净流入1614.86万元

Core Viewpoint - The stock of Zhifei Biological has shown fluctuations, with a recent increase of 2.02% and a year-to-date decline of 19.32%, indicating potential volatility in the market [1][2]. Company Overview - Zhifei Biological, established on July 20, 1995, and listed on September 28, 2010, is based in Chongqing and specializes in the research, production, and sales of vaccines and biological products [1]. - The company's revenue composition includes 88.84% from agency products, 10.15% from self-developed products, and 1.00% from other sources [1]. Financial Performance - For the period from January to September 2025, Zhifei Biological reported a revenue of 7.627 billion yuan, a year-on-year decrease of 66.53%, and a net profit attributable to shareholders of -1.206 billion yuan, a decline of 156.10% [2]. - Cumulatively, the company has distributed 7.318 billion yuan in dividends since its A-share listing, with 3.194 billion yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Zhifei Biological was 131,600, a decrease of 3.17% from the previous period, with an average of 10,750 shares held per shareholder, an increase of 3.28% [2]. - The top ten circulating shareholders include significant institutional investors, with notable reductions in holdings for several funds, indicating potential shifts in investor sentiment [3].